mRNA Flu Shot, New Myeloma Class, and Europe's August Heat Emergency
An mRNA flu vaccine nears FDA approval, a new cancer drug class advances, Europe warns of a fourth heatwave, and antibiotic resistance climbs.
By Dr. Asher Knippel
The first day of August brings two landmark regulatory countdowns in the United States, a worsening heat emergency with direct consequences for Mediterranean communities, and a sobering global account of antibiotic resistance — along with five-year trial data that confirm a new standard of care in bladder cancer.
Friday, 1 August: The World's First mRNA Flu Vaccine Awaits an FDA Decision in Four Days
Moderna's mFLUSIVA (mRNA-1010) is four days from its FDA target decision date (PDUFA: 5 August 2026), and the regulatory climate is unusually favourable. On 18 June, the FDA's Vaccines and Related Biological Products Advisory Committee voted nine to zero that the vaccine's benefits outweigh its risks for adults aged 50 and older. If approved, mFLUSIVA would be the first mRNA-based seasonal influenza vaccine licensed anywhere in the United States, ending more than eight decades of reliance on egg-grown production. The platform's most consequential practical advantage is manufacturing speed: the current six-month production cycle could compress to two or three months, meaning vaccine composition can be updated far closer to the moment when circulating strains are actually identified — a structural fix for the annual problem of flu vaccine mismatches. The FDA is applying a split approval pathway: traditional approval for adults aged 50–64, and accelerated approval for those aged 65 and older pending a postmarketing study commitment. Parallel regulatory reviews are under way in Europe, Canada, and Australia.
Around 17 August: A New Class of Cancer Drug Seeks FDA Clearance for Multiple Myeloma
Bristol Myers Squibb's iberdomide is a cereblon E3 ligase modulator (CELMoD) — an entirely new mechanistic class of cancer medicine — awaiting an FDA verdict on 17 August for use in combination with daratumumab and dexamethasone in patients with relapsed or refractory multiple myeloma (RRMM). The application carries both breakthrough-therapy designation and priority review, built on data from the Phase 3 EXCALIBER-RRMM study measuring minimal residual disease (MRD) negativity — a validated surrogate increasingly accepted as predictive of long-term survival. Iberdomide works through the same cereblon pathway that drives the current backbone drugs lenalidomide and pomalidomide, but binds with higher potency and retains activity in cells that have grown resistant to those agents. If cleared, it would be the first approved CELMoD — a meaningful advance for a disease that remains incurable for most patients.
July 2026: Five-Year Data from CheckMate 274 Confirm Nivolumab's Durable Benefit in Bladder Cancer
Updated five-year follow-up from the Phase 3 CheckMate 274 trial, published in Annals of Oncology, show that adjuvant nivolumab delivers lasting benefit after surgery in patients with high-risk muscle-invasive urothelial carcinoma. Across the full trial population, median disease-free survival was 21.9 months with nivolumab versus 11.0 months with placebo; at 60 months, 36.4% of nivolumab patients remained disease-free compared with 30.9% on placebo. The effect was most pronounced in patients with PD-L1 expression of at least 1%, where median disease-free survival reached 55.5 months with nivolumab against 8.4 months with placebo — a sixfold difference. In the muscle-invasive bladder cancer subgroup, median overall survival reached 61.2 months with nivolumab versus 38.2 months with placebo — a difference of nearly two years. Bladder cancer affects roughly 614,000 people annually worldwide; these data support adjuvant nivolumab as a durable standard of care in high-risk, post-surgical cases.
1 August, Ongoing: Europe's Fourth Heatwave of 2026 Is Tracking toward the Mediterranean
A fourth heat dome of the summer is forecast to build across Western and Central Europe and the Mediterranean basin in early August, extending a pattern that has already extracted a steep human cost. The June wave alone was linked to preliminary estimates of more than 4,000 excess deaths across Western Europe, with Belgium recording 1,222 additional deaths, Spain's Carlos III Health Institute attributing at least 1,028 heat-related deaths to the event, and the Netherlands adding roughly 480 excess deaths in a single week. For people in Cyprus and the eastern Mediterranean, the risk profile is both familiar and urgent: extreme heat accelerates dehydration, raises cardiac and renal strain, and increases the risk of acute kidney injury, particularly in those over 65, those taking diuretics or ACE inhibitors, and anyone active outdoors during midday hours. Public-health agencies across the region advise staying indoors between 11:00 and 17:00, drinking at least 1.5–2 litres of water even without feeling thirsty, checking on elderly or isolated neighbours daily, and contacting a clinician promptly if confusion, dizziness, or significantly reduced urine output occurs.
May–July 2026: One in Three Infections in the Eastern Mediterranean Now Resist Antibiotics
A landmark WHO surveillance analysis — whose findings underpinned the World Health Assembly's adoption of the updated Global Action Plan on Antimicrobial Resistance 2026–2036 in May — found that one in six laboratory-confirmed bacterial infections worldwide were already resistant to first-line antibiotics in 2023. The burden is not evenly distributed: in the WHO Eastern Mediterranean Region, which includes Cyprus, the proportion rises to one in three — double the global average. Resistance rates rose in more than 40% of the pathogen-antibiotic combinations tracked between 2018 and 2023, with annual increases averaging 5–15%. The new ten-year GAP commits member states to strengthening infection prevention and control in hospitals, enforcing antibiotic stewardship programmes, and regulating antibiotic use in agriculture — a significant driver of resistance spread in the eastern Mediterranean's farming communities. Clinicians in Cyprus are encouraged to follow updated EUCAST breakpoints, report resistance data to national surveillance networks, and remind patients that completing a prescribed antibiotic course — and never self-prescribing — matters more now than it has for decades.
The reporting above is journalistic and does not constitute medical advice. Consult a qualified clinician or pharmacist before changing any medication, vaccine schedule, or treatment plan.